nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP2C8—Spironolactone—dilated cardiomyopathy	0.26	0.409	CbGbCtD
Methadone—ABCB1—Lisinopril—dilated cardiomyopathy	0.2	0.314	CbGbCtD
Methadone—ABCB1—Spironolactone—dilated cardiomyopathy	0.176	0.277	CbGbCtD
Methadone—Hypotensive—Furosemide—dilated cardiomyopathy	0.0177	0.051	CcSEcCtD
Methadone—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.0135	0.0389	CcSEcCtD
Methadone—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.0102	0.0293	CcSEcCtD
Methadone—Drug interaction—Furosemide—dilated cardiomyopathy	0.00696	0.0201	CcSEcCtD
Methadone—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00664	0.0191	CcSEcCtD
Methadone—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.00633	0.0182	CcSEcCtD
Methadone—Disopyramide—SCN5A—dilated cardiomyopathy	0.00624	0.513	CrCbGaD
Methadone—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.00598	0.0172	CcSEcCtD
Methadone—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00578	0.0167	CcSEcCtD
Methadone—Swelling—Furosemide—dilated cardiomyopathy	0.00532	0.0153	CcSEcCtD
Methadone—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00522	0.0151	CcSEcCtD
Methadone—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00499	0.0144	CcSEcCtD
Methadone—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00485	0.014	CcSEcCtD
Methadone—Irritability—Furosemide—dilated cardiomyopathy	0.00448	0.0129	CcSEcCtD
Methadone—Urinary retention—Furosemide—dilated cardiomyopathy	0.00446	0.0128	CcSEcCtD
Methadone—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00434	0.0125	CcSEcCtD
Methadone—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00431	0.0124	CcSEcCtD
Methadone—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00428	0.0123	CcSEcCtD
Methadone—Confusional state—Spironolactone—dilated cardiomyopathy	0.00427	0.0123	CcSEcCtD
Methadone—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00427	0.0123	CcSEcCtD
Methadone—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00424	0.0122	CcSEcCtD
Methadone—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00415	0.012	CcSEcCtD
Methadone—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00379	0.0109	CcSEcCtD
Methadone—Somnolence—Spironolactone—dilated cardiomyopathy	0.00377	0.0109	CcSEcCtD
Methadone—Drowsiness—Furosemide—dilated cardiomyopathy	0.00361	0.0104	CcSEcCtD
Methadone—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00349	0.0101	CcSEcCtD
Methadone—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00349	0.0101	CcSEcCtD
Methadone—Sweating—Furosemide—dilated cardiomyopathy	0.00346	0.00998	CcSEcCtD
Methadone—Urticaria—Spironolactone—dilated cardiomyopathy	0.00337	0.0097	CcSEcCtD
Methadone—Irritability—Lisinopril—dilated cardiomyopathy	0.00336	0.00968	CcSEcCtD
Methadone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00335	0.00965	CcSEcCtD
Methadone—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00335	0.00964	CcSEcCtD
Methadone—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00321	0.00926	CcSEcCtD
Methadone—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00315	0.00907	CcSEcCtD
Methadone—Visual impairment—Furosemide—dilated cardiomyopathy	0.00313	0.00901	CcSEcCtD
Methadone—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00312	0.00899	CcSEcCtD
Methadone—Pruritus—Spironolactone—dilated cardiomyopathy	0.003	0.00864	CcSEcCtD
Methadone—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00296	0.00854	CcSEcCtD
Methadone—Orphenadrine—SCN5A—dilated cardiomyopathy	0.00292	0.24	CrCbGaD
Methadone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.0029	0.00835	CcSEcCtD
Methadone—Arrhythmia—Furosemide—dilated cardiomyopathy	0.0029	0.00835	CcSEcCtD
Methadone—Erythema—Furosemide—dilated cardiomyopathy	0.00282	0.00814	CcSEcCtD
Methadone—Dizziness—Spironolactone—dilated cardiomyopathy	0.0028	0.00807	CcSEcCtD
Methadone—Weight increased—Lisinopril—dilated cardiomyopathy	0.00277	0.00798	CcSEcCtD
Methadone—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00275	0.00793	CcSEcCtD
Methadone—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00271	0.00782	CcSEcCtD
Methadone—Vomiting—Spironolactone—dilated cardiomyopathy	0.00269	0.00776	CcSEcCtD
Methadone—Rash—Spironolactone—dilated cardiomyopathy	0.00267	0.0077	CcSEcCtD
Methadone—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00267	0.00769	CcSEcCtD
Methadone—Headache—Spironolactone—dilated cardiomyopathy	0.00265	0.00765	CcSEcCtD
Methadone—Sweating—Lisinopril—dilated cardiomyopathy	0.0026	0.00749	CcSEcCtD
Methadone—Agitation—Furosemide—dilated cardiomyopathy	0.00259	0.00748	CcSEcCtD
Methadone—Vertigo—Furosemide—dilated cardiomyopathy	0.00254	0.00731	CcSEcCtD
Methadone—Nausea—Spironolactone—dilated cardiomyopathy	0.00252	0.00725	CcSEcCtD
Methadone—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00248	0.00714	CcSEcCtD
Methadone—Hallucination—Lisinopril—dilated cardiomyopathy	0.00242	0.00698	CcSEcCtD
Methadone—Dry mouth—Furosemide—dilated cardiomyopathy	0.00235	0.00678	CcSEcCtD
Methadone—Confusional state—Furosemide—dilated cardiomyopathy	0.00232	0.0067	CcSEcCtD
Methadone—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.0023	0.00664	CcSEcCtD
Methadone—Shock—Furosemide—dilated cardiomyopathy	0.00227	0.00653	CcSEcCtD
Methadone—Flushing—Lisinopril—dilated cardiomyopathy	0.00226	0.00651	CcSEcCtD
Methadone—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00226	0.0065	CcSEcCtD
Methadone—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00223	0.00642	CcSEcCtD
Methadone—Anorexia—Furosemide—dilated cardiomyopathy	0.0022	0.00633	CcSEcCtD
Methadone—Chills—Lisinopril—dilated cardiomyopathy	0.00218	0.00629	CcSEcCtD
Methadone—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00217	0.00627	CcSEcCtD
Methadone—Hypotension—Furosemide—dilated cardiomyopathy	0.00215	0.00621	CcSEcCtD
Methadone—Erythema—Lisinopril—dilated cardiomyopathy	0.00212	0.00611	CcSEcCtD
Methadone—Somnolence—Furosemide—dilated cardiomyopathy	0.00205	0.0059	CcSEcCtD
Methadone—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00204	0.00587	CcSEcCtD
Methadone—Decreased appetite—Furosemide—dilated cardiomyopathy	0.002	0.00577	CcSEcCtD
Methadone—Tremor—Lisinopril—dilated cardiomyopathy	0.00199	0.00572	CcSEcCtD
Methadone—Pain—Furosemide—dilated cardiomyopathy	0.00197	0.00568	CcSEcCtD
Methadone—Constipation—Furosemide—dilated cardiomyopathy	0.00197	0.00568	CcSEcCtD
Methadone—Vertigo—Lisinopril—dilated cardiomyopathy	0.0019	0.00549	CcSEcCtD
Methadone—Syncope—Lisinopril—dilated cardiomyopathy	0.0019	0.00548	CcSEcCtD
Methadone—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.0019	0.00547	CcSEcCtD
Methadone—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00188	0.00543	CcSEcCtD
Methadone—Palpitations—Lisinopril—dilated cardiomyopathy	0.00187	0.0054	CcSEcCtD
Methadone—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00186	0.00537	CcSEcCtD
Methadone—Urticaria—Furosemide—dilated cardiomyopathy	0.00183	0.00528	CcSEcCtD
Methadone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00182	0.00525	CcSEcCtD
Methadone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00182	0.00525	CcSEcCtD
Methadone—Anxiety—Lisinopril—dilated cardiomyopathy	0.0018	0.00518	CcSEcCtD
Methadone—Diphenhydramine—SLC22A5—dilated cardiomyopathy	0.00178	0.146	CrCbGaD
Methadone—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00176	0.00508	CcSEcCtD
Methadone—Confusional state—Lisinopril—dilated cardiomyopathy	0.00174	0.00502	CcSEcCtD
Methadone—Oedema—Lisinopril—dilated cardiomyopathy	0.00173	0.00498	CcSEcCtD
Methadone—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00173	0.00498	CcSEcCtD
Methadone—Shock—Lisinopril—dilated cardiomyopathy	0.0017	0.0049	CcSEcCtD
Methadone—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0017	0.00489	CcSEcCtD
Methadone—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00169	0.00488	CcSEcCtD
Methadone—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00169	0.00486	CcSEcCtD
Methadone—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00167	0.00482	CcSEcCtD
Methadone—Asthenia—Furosemide—dilated cardiomyopathy	0.00165	0.00477	CcSEcCtD
Methadone—Anorexia—Lisinopril—dilated cardiomyopathy	0.00165	0.00475	CcSEcCtD
Methadone—Pruritus—Furosemide—dilated cardiomyopathy	0.00163	0.0047	CcSEcCtD
Methadone—Hypotension—Lisinopril—dilated cardiomyopathy	0.00162	0.00466	CcSEcCtD
Methadone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00158	0.00454	CcSEcCtD
Methadone—Insomnia—Lisinopril—dilated cardiomyopathy	0.00156	0.00451	CcSEcCtD
Methadone—Somnolence—Lisinopril—dilated cardiomyopathy	0.00154	0.00443	CcSEcCtD
Methadone—Dizziness—Furosemide—dilated cardiomyopathy	0.00152	0.00439	CcSEcCtD
Methadone—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.0015	0.00433	CcSEcCtD
Methadone—Constipation—Lisinopril—dilated cardiomyopathy	0.00148	0.00426	CcSEcCtD
Methadone—Pain—Lisinopril—dilated cardiomyopathy	0.00148	0.00426	CcSEcCtD
Methadone—Vomiting—Furosemide—dilated cardiomyopathy	0.00147	0.00422	CcSEcCtD
Methadone—Rash—Furosemide—dilated cardiomyopathy	0.00145	0.00419	CcSEcCtD
Methadone—Dermatitis—Furosemide—dilated cardiomyopathy	0.00145	0.00418	CcSEcCtD
Methadone—Headache—Furosemide—dilated cardiomyopathy	0.00144	0.00416	CcSEcCtD
Methadone—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00142	0.00411	CcSEcCtD
Methadone—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00141	0.00407	CcSEcCtD
Methadone—Urticaria—Lisinopril—dilated cardiomyopathy	0.00137	0.00396	CcSEcCtD
Methadone—Nausea—Furosemide—dilated cardiomyopathy	0.00137	0.00395	CcSEcCtD
Methadone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00137	0.00394	CcSEcCtD
Methadone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00137	0.00394	CcSEcCtD
Methadone—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00127	0.00367	CcSEcCtD
Methadone—Asthenia—Lisinopril—dilated cardiomyopathy	0.00124	0.00358	CcSEcCtD
Methadone—Phenoxybenzamine—ADRB2—dilated cardiomyopathy	0.00123	0.101	CrCbGaD
Methadone—Pruritus—Lisinopril—dilated cardiomyopathy	0.00122	0.00353	CcSEcCtD
Methadone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00118	0.00341	CcSEcCtD
Methadone—Dizziness—Lisinopril—dilated cardiomyopathy	0.00114	0.0033	CcSEcCtD
Methadone—Vomiting—Lisinopril—dilated cardiomyopathy	0.0011	0.00317	CcSEcCtD
Methadone—Rash—Lisinopril—dilated cardiomyopathy	0.00109	0.00314	CcSEcCtD
Methadone—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00109	0.00314	CcSEcCtD
Methadone—Headache—Lisinopril—dilated cardiomyopathy	0.00108	0.00312	CcSEcCtD
Methadone—Nausea—Lisinopril—dilated cardiomyopathy	0.00103	0.00296	CcSEcCtD
Methadone—OPRM1—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	1.47e-05	0.00363	CbGpPWpGaD
Methadone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	1.46e-05	0.0036	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	1.46e-05	0.00359	CbGpPWpGaD
Methadone—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	1.45e-05	0.00358	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	1.45e-05	0.00357	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	1.45e-05	0.00357	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	1.43e-05	0.00351	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	1.38e-05	0.00341	CbGpPWpGaD
Methadone—OPRK1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	1.38e-05	0.00341	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—ANKRD1—dilated cardiomyopathy	1.38e-05	0.00341	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	1.35e-05	0.00332	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	1.34e-05	0.0033	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	1.33e-05	0.00328	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	1.32e-05	0.00325	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	1.32e-05	0.00325	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	1.31e-05	0.00322	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	1.31e-05	0.00322	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	1.3e-05	0.00321	CbGpPWpGaD
Methadone—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	1.3e-05	0.0032	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—TAZ—dilated cardiomyopathy	1.3e-05	0.0032	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	1.29e-05	0.00318	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	1.25e-05	0.00308	CbGpPWpGaD
Methadone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	1.23e-05	0.00304	CbGpPWpGaD
Methadone—HTR3A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	1.23e-05	0.00303	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	1.23e-05	0.00302	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	1.22e-05	0.00299	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	1.21e-05	0.00299	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	1.18e-05	0.00291	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—SDHA—dilated cardiomyopathy	1.18e-05	0.0029	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	1.18e-05	0.0029	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	1.17e-05	0.00288	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	1.17e-05	0.00287	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	1.15e-05	0.00284	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	1.14e-05	0.00282	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	1.11e-05	0.00275	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	1.1e-05	0.00272	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	1.1e-05	0.00272	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	1.09e-05	0.00268	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	1.08e-05	0.00267	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—ANKRD1—dilated cardiomyopathy	1.06e-05	0.00261	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	1.06e-05	0.00261	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	1.06e-05	0.0026	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	1.05e-05	0.00259	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	1.03e-05	0.00253	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	1e-05	0.00247	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—TAZ—dilated cardiomyopathy	9.95e-06	0.00245	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	9.94e-06	0.00245	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	9.89e-06	0.00244	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	9.86e-06	0.00243	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	9.52e-06	0.00235	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	9.45e-06	0.00233	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	9.28e-06	0.00229	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	9.19e-06	0.00226	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—SDHA—dilated cardiomyopathy	9e-06	0.00222	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	8.99e-06	0.00221	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	8.64e-06	0.00213	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	8.49e-06	0.00209	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	8.45e-06	0.00208	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.41e-06	0.00207	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.41e-06	0.00207	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—AGT—dilated cardiomyopathy	8.06e-06	0.00199	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	8.05e-06	0.00198	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	7.84e-06	0.00193	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.82e-06	0.00193	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	7.82e-06	0.00193	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.64e-06	0.00188	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.64e-06	0.00188	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	7.63e-06	0.00188	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.58e-06	0.00187	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	7.42e-06	0.00183	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	7.42e-06	0.00183	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	7.38e-06	0.00182	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	7.38e-06	0.00182	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	7.1e-06	0.00175	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—AGT—dilated cardiomyopathy	7.06e-06	0.00174	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.9e-06	0.0017	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.88e-06	0.0017	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	6.86e-06	0.00169	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ANKRD1—dilated cardiomyopathy	6.8e-06	0.00167	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	6.7e-06	0.00165	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	6.7e-06	0.00165	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	6.64e-06	0.00164	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	6.64e-06	0.00164	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	6.62e-06	0.00163	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	6.48e-06	0.0016	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	6.48e-06	0.0016	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.47e-06	0.00159	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—TAZ—dilated cardiomyopathy	6.39e-06	0.00157	CbGpPWpGaD
Methadone—HTR3A—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.37e-06	0.00157	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	6.25e-06	0.00154	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	6.24e-06	0.00154	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	6.24e-06	0.00154	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	6.23e-06	0.00153	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	6.17e-06	0.00152	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	6.17e-06	0.00152	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.14e-06	0.00151	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	6.05e-06	0.00149	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.03e-06	0.00149	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	5.97e-06	0.00147	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.88e-06	0.00145	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	5.83e-06	0.00144	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	5.8e-06	0.00143	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—SDHA—dilated cardiomyopathy	5.78e-06	0.00142	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	5.76e-06	0.00142	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	5.72e-06	0.00141	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	5.67e-06	0.0014	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	5.66e-06	0.0014	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	5.66e-06	0.0014	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	5.65e-06	0.00139	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	5.61e-06	0.00138	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.57e-06	0.00137	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.49e-06	0.00135	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	5.41e-06	0.00133	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	5.38e-06	0.00133	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.35e-06	0.00132	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	5.26e-06	0.0013	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.15e-06	0.00127	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	5.14e-06	0.00127	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	5.1e-06	0.00126	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.08e-06	0.00125	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	5.02e-06	0.00124	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	5.01e-06	0.00124	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	4.89e-06	0.00121	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	4.89e-06	0.0012	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	4.83e-06	0.00119	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.81e-06	0.00119	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	4.8e-06	0.00118	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.77e-06	0.00117	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	4.72e-06	0.00116	CbGpPWpGaD
Methadone—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	4.71e-06	0.00116	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	4.68e-06	0.00115	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.55e-06	0.00112	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	4.55e-06	0.00112	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.51e-06	0.00111	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.51e-06	0.00111	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.46e-06	0.0011	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	4.44e-06	0.00109	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	4.4e-06	0.00109	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	4.37e-06	0.00108	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	4.35e-06	0.00107	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.33e-06	0.00107	CbGpPWpGaD
Methadone—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	4.26e-06	0.00105	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.2e-06	0.00103	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.18e-06	0.00103	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.13e-06	0.00102	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	4.13e-06	0.00102	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.06e-06	0.001	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	4.02e-06	0.00099	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	4e-06	0.000986	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AGT—dilated cardiomyopathy	3.99e-06	0.000984	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	3.98e-06	0.000981	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.96e-06	0.000975	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.96e-06	0.000975	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.79e-06	0.000935	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	3.79e-06	0.000934	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.77e-06	0.000928	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	3.76e-06	0.000927	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.68e-06	0.000907	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AGT—dilated cardiomyopathy	3.63e-06	0.000893	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.56e-06	0.000878	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	3.53e-06	0.00087	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.47e-06	0.000855	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	3.4e-06	0.000839	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	3.37e-06	0.000831	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.35e-06	0.000824	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.35e-06	0.000824	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.29e-06	0.000811	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.21e-06	0.00079	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—GPX1—dilated cardiomyopathy	3.19e-06	0.000787	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—CD36—dilated cardiomyopathy	3.11e-06	0.000766	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.11e-06	0.000766	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	3.09e-06	0.000761	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	3.06e-06	0.000755	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.04e-06	0.00075	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.01e-06	0.000742	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.99e-06	0.000735	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.91e-06	0.000716	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.9e-06	0.000716	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.89e-06	0.000711	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.87e-06	0.000707	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.83e-06	0.000697	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—AGT—dilated cardiomyopathy	2.8e-06	0.00069	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.66e-06	0.000656	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	2.63e-06	0.000647	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.62e-06	0.000645	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.6e-06	0.00064	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.59e-06	0.000639	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.57e-06	0.000634	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.56e-06	0.00063	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.52e-06	0.00062	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.48e-06	0.000611	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.48e-06	0.00061	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—GPX1—dilated cardiomyopathy	2.45e-06	0.000602	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AGT—dilated cardiomyopathy	2.44e-06	0.000602	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.44e-06	0.000601	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.43e-06	0.000599	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—CD36—dilated cardiomyopathy	2.38e-06	0.000587	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.37e-06	0.000583	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.34e-06	0.000576	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.24e-06	0.000552	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—AGT—dilated cardiomyopathy	2.14e-06	0.000528	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AGT—dilated cardiomyopathy	2.14e-06	0.000528	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.13e-06	0.000525	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.13e-06	0.000524	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	2.12e-06	0.000523	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.1e-06	0.000517	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.08e-06	0.000511	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	2.07e-06	0.000509	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.02e-06	0.000498	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.97e-06	0.000485	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.89e-06	0.000467	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	1.86e-06	0.000459	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.82e-06	0.000448	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AGT—dilated cardiomyopathy	1.81e-06	0.000446	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.73e-06	0.000425	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.7e-06	0.000418	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GPX1—dilated cardiomyopathy	1.57e-06	0.000387	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	1.53e-06	0.000378	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CD36—dilated cardiomyopathy	1.53e-06	0.000377	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.5e-06	0.000371	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	1.49e-06	0.000368	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.49e-06	0.000366	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.46e-06	0.000359	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AGT—dilated cardiomyopathy	1.38e-06	0.000339	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	1.35e-06	0.000332	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	1.33e-06	0.000328	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	1.29e-06	0.000319	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.26e-06	0.000309	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	1.19e-06	0.000292	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	1.17e-06	0.000287	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.16e-06	0.000286	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.16e-06	0.000285	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	1.16e-06	0.000285	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.13e-06	0.000278	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.09e-06	0.000269	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	1.08e-06	0.000267	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.06e-06	0.000262	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	1.05e-06	0.00026	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	1.04e-06	0.000256	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.02e-06	0.000251	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.02e-06	0.00025	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	9.57e-07	0.000236	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	9.49e-07	0.000234	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	9.25e-07	0.000228	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	9e-07	0.000222	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	8.61e-07	0.000212	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	8.11e-07	0.0002	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	7.14e-07	0.000176	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	6.95e-07	0.000171	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	6.26e-07	0.000154	CbGpPWpGaD
